Standard BioTools Reports Preliminary Revenue Results for 2025
Source: GlobeNewsWire | January 08, 2026
Significant Revenue Growth
BOSTON, Jan. 08, 2026 - Standard BioTools Inc. (NASDAQ: LAB) has released its preliminary and unaudited revenue figures for the fourth quarter and full year 2025. The company anticipates a combined revenue of approximately $185 million for the entire year, with revenue from continuing operations expected to be around $85 million.
For the fourth quarter of 2025, Standard BioTools projects a combined revenue of roughly $56 million, of which about $24 million comes from continuing operations.
CEO Insights on Performance
Michael Egholm, PhD, CEO of Standard BioTools, stated, “Our 2025 performance reflected steady execution, ending the year above our guidance range and exceeding expectations for both combined and continuing operations.” He emphasized the team's focus amid challenging market conditions, saying, “We managed what we could control to drive the business forward.”
Dr. Egholm further noted, “We continued our path toward profitability by taking targeted actions to streamline the organization and sharpen our operating model, which strengthened our foundation and made us a leaner organization.”
Future Directions and Opportunities
Looking ahead to 2026, Standard BioTools highlights the ongoing sale of SomaLogic to Illumina, expected to close in the first half of the year. Upon closure, the company anticipates having approximately $550 million in cash, alongside a base business poised for positive adjusted EBITDA. This strong financial position will provide the company with significant strategic flexibility.
- Projected 2025 Revenue: $185 million
- Expected Fourth Quarter Revenue: $56 million
- Revenue from Continuing Operations: $85 million
- Cash Anticipated at SomaLogic Closure: $550 million
Upcoming Financial Report
Standard BioTools plans to release its detailed fourth quarter and full year 2025 financial results later this quarter. During this release, the company will provide a comprehensive discussion of its financial outcomes for 2025 and its outlook for the year ahead.
It is important to note that the preliminary revenue figures are based on current expectations and may be adjusted following the completion of annual audit procedures.
About Standard BioTools
Standard BioTools Inc. (NASDAQ: LAB) is a leader in providing next-generation technologies essential for biomedical research. The company's innovative solutions, including the proprietary SomaScan, mass cytometry, and microfluidics technologies, enable researchers to develop better medicines faster. Standard BioTools partners with academic, government, and clinical laboratories worldwide to address critical needs in translational and clinical research.
Forward-Looking Statements
This press release contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. These statements include anticipated future performance, including revenue and operational goals. Naturally, such forward-looking statements carry risks and uncertainties that could lead actual results to differ from expectations. For further details, refer to the “Risk Factors” section in Standard BioTools’ annual report.